Abstract
While medicines have been assessed in terms of their benefits and risks since health authorities started requiring clinical studies in the 1960s, only recently more formal approaches for conducting benefit–risk evaluations have emerged. Both the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) are in the process of implementing qualitative benefit–risk frameworks, but at the same time, the industry and some other stakeholders have started to pilot quantitative benefit–risk methods in regulatory settings. Multi-criteria decision analysis seems to emerge as one of the preferred quantitative methods, in particular for medicines with a complex multifactorial benefit–risk profile. In this chapter a number of case studies of the use of MCDA for benefit–risk assessment during drug development and for regulatory purposes will be described. Based on these case studies, technical and operational progress, learnings, and challenges will be discussed, and recommendations will be made when and how MCDA can be used for the benefit–risk assessment of medicines. These conclusions will be contextualized within the broader debate of the use of formal benefit–risk methods as decision tools mainly for regulatory purposes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Bibliography
Bass R (1987) Risk-benefit decisions in product license applications. In: Walker SR, Asscher AW (eds) Medicines and risk/benefit decisions. MTP Press Limited, Lancaster, pp 127–134
Belton V, Stewart TJ (2002) Multiple criteria decision analysis: an integrated approach. Kluwer Academic Publishers, Boston
CIOMS Working Group IV (1998) Benefit-risk balance for marketed drugs: evaluating safety signals. CIOMS, Geneva
Coplan PM, Noel RA, Levitan BS, Ferguson J, Mussen F (2011) Development of a framework for enhancing the transparency, reproducibility and communication of the benefit-risk balance of medicines. Clin Pharmacol Therapeutics 89:312–315
Eichler HG, Bloechl-Daum B, Brasseur D, Breckenridge A, Leufkens H, Raine J, Salmonson T, Schneider CK, Rasi G (2013) The risks of risk aversion in drug regulation. Nat Rev Drug Discov 12:907–916
European Medicines Agency (2007) Report of the CHMP working group on benefit-risk assessment models and methodshttp://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/01/WC500069668.pdf
European Medicines Agency (2010) Benefit-risk methodology project – work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/10/WC500097750.pdf
European Medicines Agency (2011) Benefit-risk assessment methodology project. Work package 3. Field tests. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500112088.pdf
European Medicines Agency (2012) Benefit-risk assessment methodology project. Work package 4. Benefit risk tools and processes. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/03/WC500123819.pdf
Food and Drug Administration (2013). Structured approach to benefit-risk assessment in drug regulatory decision-making – draft PDUFA V implementation plan. http://www.fda.gov/downloads/ForIndustry/UserFees/PrescriptionDrugUserFee/UCM329758.pdf
Food and Drug Administration (2015) Patient preference information – submission, review in PMAs, HDE applications, and De Novo requests, and inclusion in device labeling. http://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.pdf
Felli JC, Noel RA, Cavazzoni PA (2009) A multiattribute model for evaluating the benefit-risk profiles of treatment alternatives. Med Decis Making 29:104
Goetghebeur MM, Wagner M, Nikodem M, Zyla A, Micaleff A, Amzal B (2016) Pragmatic multicriteria decision analysis (MCDA) combined with advanced pharmacoepidemiology for benefit-risk assessments of medicines adapted to the real-life constraints of regulators: development and case study. Ther Innov Regul Sci. 50:620-631
Ho MP, Gonzalez JM, Lerner HP, Neuland CY, Whang JM, McMurry-Heath M, Hauber AM, Irony T (2015) Incorporating patient-preference evidence into regulatory decision making. Surg Endosc 29:2984–2993
Hughes D et al (2013) IMI-PROTECT Benefit-Risk Group. Recommendations for the methodology and visualisation techniques to be used in the assessment of benefit and risk of medicines. http://www.imi-protect.eu/documents/HughesetalRecommendationsforthemethodologyandvisualisationtechniquestobeusedintheassessmento.pdf
International Council for Harmonisation (2016). Revision of M4E guideline on enhancing the format and structure of benefit-risk information in ICH – Efficacy M4E(R2)http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4E_R2_Efficacy/M4E_R2__Step_4.pdf
Institute of Medicine (2014) Characterizing and communicating uncertainty in the assessment of benefits and risks of pharmaceutical products: workshop summary http://nationalacademies.org/hmd/reports/2014/characterizing-and-communicating-uncertainty-in-the-assessment-of-benefits-and-risks-of-pharmaceutical-products.aspx
Marcelon L, Verstraeten T, Dominiak-Felden G, Simondon F (2016) Quantitative benefit-risk assessment by MCDA of the quadrivalent HPV vaccine for preventing anal cancer in males. Expert Rev Vaccines 15:139–148 http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/CTD/M4E_R2_Efficacy/M4E_R2__Step_4.pdf
Marsh K, IJzerman M, Thokala P, Baltussen R, Boysen M, Kaló Z, Lönngren T, Mussen F, Peacock S, Watkins J, Devlin N (2016) Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA Emerging Good Practices Task Force. Value Health 19:125–137
Mt-Isa S et al (2014) Review of methodologies for benefit and risk assessment of medication. http://www.imi-protect.eu/documents/ShahruletalReviewofmethodologiesforbenefitandriskassessmentofmedicationMay2013.pdf
Mussen F, Salek S, Walker S (2007) A quantitative approach to benefit-risk assessment of medicines – part 1: the development of a new model using multi-criteria decision analysis. Pharmacoepidemiol Drug Saf 16:S2–S16
Mussen F, Salek S, Walker S (2002) What is the best model for assessing the benefit/risk ratio of my product? In: VandenBurg M, Salek S, Wight LJ (eds) Dilemmas and solutions in global drug development: your questions answered. PJB Publications Ltd, London, pp IIC3 1–IIC3 15
Phillips LD, Fasolo B, Zafiropoulos N, Beyer A (2011) Is quantitative benefit-risk modeling of drugs desirable or possible? Drug Discov Today Technol 8:e3–e10
Phillips LD, Fasolo B, Zafiropoulous N et al (2013) Modelling the risk-benefit impact of H1N1 influenza vaccines. Eur J Public Health 23:674–678
Quartey G, Wang J (2011) Statistical aspects in comparative benefit-risk assessment: challenges and opportunities for pharmaceutical statisticians. Pharm Stat 11:82–85
Sarac SB, Rasmussen CH, Rasmussen MA, Hallgreen CE, Søeborg T, Colding-Jørgensen M, Christensen PK, Thirstrup S, Mosekilde E (2012) A comprehensive approach to benefit-risk assessment in drug development. Basic Clin Pharmacol Toxicol 111:65–72
Russo JE, Schoemaker PH (2002) Winning decisions – getting it right the first time. In: A currency book, 1st edn. Doubleday, New York
Tervonen T, van Valkenhoef G, Buskens E, Hillege HL, Postmus D (2011) A stochastic multi-criteria model for evidence-based decision making in drug benefit-risk analysis. Stat Med 30:1419–1428
Tervonen T, Naci H, van Valkenhoef G et al (2015) Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Med Decis Making 35:859–871
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Mussen, F. (2017). Benefit–Risk Assessment. In: Marsh, K., Goetghebeur, M., Thokala, P., Baltussen, R. (eds) Multi-Criteria Decision Analysis to Support Healthcare Decisions. Springer, Cham. https://doi.org/10.1007/978-3-319-47540-0_7
Download citation
DOI: https://doi.org/10.1007/978-3-319-47540-0_7
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-47538-7
Online ISBN: 978-3-319-47540-0
eBook Packages: MedicineMedicine (R0)